Dominari Holdings Inc. (BP2A)
XFRA 
Summary
BP2A Chart
Dominari Holdings Inc. Strengthens Team with Appointment of Experienced Accounting Team
Edward Deignan Appointed as VP of Finance and Accounting Kyle Degruttola Appointed as Controller NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Dominari Holdings Inc. (Nasdaq:DOMH) (the "Company") today announced that it has appointed Edward Deignan as Vice President of Finance and Accounting and Kyle Degruttola as Controller. Together, they bring decades of accounting and finance leadership experience from various multi-national and public sector organizations.
Dominari Securities LLC Announces Appointment of Capital Markets Veteran James Hopkins as Managing Director Head of Capital Markets
Hopkins has Led and Structured Hundreds of Capital Markets Transactions NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Dominari Holdings Inc. (Nasdaq:DOMH) (the "Company") today noted that its wholly-owned subsidiary, Dominari Securities LLC ("Dominari"), announced that it has further expanded its practice with the appointment of capital markets veteran James (Jimmy) Hopkins as Managing Director Head of Capital Markets. Mr. Kyle Wool, CEO of Dominari Securities LLC, commented, "Our commitment to positioning Dominari as a full-service, diversified financial services firm and growing our business remains stronger than ever, and Jimmy has a proven record of success with hundreds of completed transactions.
Dominari Securities LLC Receives Milestone Approval as a Nasdaq Limited Underwriting Member
NEW YORK CITY, NY / ACCESSWIRE / August 13, 2024 / Dominari Holdings Inc. (Nasdaq:DOMH) (the "Company") today announced that its wholly-owned subsidiary, Dominari Securities LLC ("Dominari"), has been approved as a Limited Underwriting Member of the Nasdaq Stock Market. This approval enables Dominari to act as a principal underwriter under Nasdaq Listing Rule 5210(m).
Dominari Holdings Inc. (BP2A) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dominari Holdings Inc. ever had a stock split?
Dominari Holdings Inc. Profile
| Capital Markets Industry | Financials Sector | Anthony C. Hayes CEO | XFRA Exchange | US0088753043 ISIN |
| US Country | 29 Employees | 15 May 2026 Last Dividend | 7 Jun 2022 Last Split | 7 Sep 1984 IPO Date |
Overview
Dominari Holdings Inc., originally known as AIkido Pharma Inc., is an eminent biotechnology enterprise established in 1967 and rebranded in December 2022. The company is strategically located in New York, New York, and dedicates its expertise to the discovery and development of innovative small-molecule anticancer therapeutics. It has forged valuable license agreements with prestigious institutions like the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences, enhancing its capacity to bring groundbreaking treatments to the market. Dominari Holdings Inc. is at the forefront of addressing some of the most challenging cancers and viral infections, leveraging its cutting-edge research to improve patient outcomes across the globe.
Products and Services
- DHA-dFdC - This pancreatic drug candidate represents a significant advancement in the treatment of pancreatic cancer. By focusing on the unique aspects of cancer cell biology, DHA-dFdC holds the promise of improving survival rates and quality of life for patients afflicted with this devastating disease.
- KPC34 - As a small molecule treatment, KPC34 is designed to target both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Its innovative approach aims to offer a more effective and less toxic alternative to traditional chemotherapy methods, potentially transforming the treatment landscape for leukemia patients.
- Antiviral Platform - In response to the global need for more robust antiviral therapies, Dominari Holdings Inc. is developing a platform that inhibits the replication of a wide array of viruses, including influenza, Ebolavirus and Marburg virus, as well as coronaviruses like SARS-CoV, MERS-CoV, and SARS-CoV-2. This effort could not only lead to effective treatments for current viral threats but also bolster our preparedness for future pandemics.
